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Methicillin-resistant Staphylococcus aureus (MRSA) is a common nosocomial and 137 
community acquired bacterium resistant to beta-lactam antibiotics such as penicillin and 138 
its derivatives. Staphylococcus aureus infections were successfully treated with penicillin 139 
until the emergence of antibiotic resistant strains of the bacterium in the late 1940s. The 140 
symptoms of MRSA are similar to S. aureus infections, including various skin infections, 141 
toxic shock syndrome, and necrotizing pneumonia. The majority of MRSA infections start 142 
in wounds and other breaches to the integrity of the skin usually caused by trauma, surgery, 143 
or medical devices. An average of two in one hundred people are carriers of MRSA, and it 144 
is a leading cause of hospital-acquired infections. MRSA derives its resistance by 145 
producing a penicillin-binding protein (PBP2a) that binds with a lower affinity to beta-146 
lactam antibiotics. In addition, there are a variety of other proteins and genetic elements 147 
that increase the pathogen’s resistance to commonly used antibiotics. The ability of MRSA 148 
to form a biofilm is a concern further enhancing resistance. Because of the difficulty in 149 
treating MRSA, alternative methods are important in combating this pathogen. 150 
Historically, metals have been used for thousands of years in medicine. It is known that 151 
copper and silver possess antimicrobial properties, however there is less knowledge on the 152 
antimicrobial effects of zinc and manganese. This project investigates the efficacy of 153 
natural dietary minerals, namely zinc (Zn) and manganese (Mn) in treating wound 154 
infections of MRSA in vitro.  155 
Experiments were conducted to establish the sub inhibitory concentration (SIC) and 156 
minimum inhibitory concentration (MIC) of Zn and Mn on three strains of MRSA. In 157 
addition, the effect of Zn and Mn on increasing MRSA sensitivity to oxacillin was 158 
 6 
determined. Finally, the effect of Zn and Mn on MRSA adhesion and invasion on human 159 
keratinocytes was studied in vitro. Future applications of this study include the use of Zn 160 
and Mn in treating wound infections of MRSA with or without antibiotics. This study is 161 
expected to contribute to the development of a topical ointment, gel, or patch that could 162 






































 Staphylococcus aureus, first discovered in the 1880s, was a significant nosocomial 199 
and community pathogen that led to fatal infections (23). The introduction of penicillin in 200 
the 1940s lead to successful treatment and control of the pathogen (20). However, by the 201 
late 1940s S. aureus strains resistant to penicillin emerged (20). Subsequently, methicillin 202 
with beta-lactamase-resistant properties was introduced in 1959 (17), however, S. aureus 203 
developed resistance to methicillin with the first case of Methicillin Resistant 204 
Staphylococcus Aureus (MRSA) reported in the United States in 1968 (20). Vancomycin 205 
is the current antibiotic of choice used to treat MRSA infections, however there are growing 206 
concerns of Vancomycin Resistant Staphylococcus aureus (17).  207 
 208 
Biology 209 
 MRSA are gram-positive cocci, catalase positive, non-motile, non-spore forming, 210 
salt tolerant facultative anaerobes (10).  MRSA viewed under scanning electron 211 
microscopy appears as characteristic grape-like clusters. MRSA is a misnomer as strains 212 
of MRSA are resistant to several beta lactam antibiotics, including penicillin, amoxicillin, 213 
oxacillin, methicillin, cephalosporin, and carbapenem (15). MRSA can be tested through 214 
broth microdilution testing, cefoxitin disk screen test, latex agglutination test for PBP2a, 215 
or plating with oxacillin (15). Warren et al. (30) reported that PCR detection for the mecA 216 
gene had a 91.7% sensitivity compared to traditional culture methods and took significantly 217 




Prevalence and Transmission 221 
 S. aureus is commonly found on skin surfaces, including the respiratory tract and 222 
nasal passageway. The pathogen has the ability to form biofilms, which presents a 223 
significant issue during cleaning of healthcare settings. The epidemiology of MRSA is 224 
commonly split into healthcare-associated MRSA (HA-MRSA) and community-associated 225 
MRSA (CA-MRSA). HA-MRSA is defined as MRSA infections that occur following 226 
healthcare setting stays or within a 12-month timeframe of a medical procedure. In HA-227 
MRSA, transmission is common via contaminated hands and hospital surfaces. In a study 228 
at Grady Memorial Hospital in Atlanta Georgia, researchers found that 7.3% of patients 229 
had nares culture positive for MRSA (14). In addition, the National Nosocomial Infections 230 
Surveillance System over a period of 12 years reported a MRSA prevalence of 60% in the 231 
intensive care unit (2). It is also known that MRSA is the leading cause of surgical site 232 
infections in community hospitals (2).  233 
 234 
Clinical Presentation and Wound Infections 235 
 Symptoms of MRSA are similar to S. aureus infections, including various skin 236 
infections such as folliculitis, cellulitis, impetigo, abscess, and boils (2). The majority of 237 
MRSA infections start in wounds and other breaches to the integrity of the skin usually 238 
caused by trauma, surgery, or medical devices. Normally, S. aureus are found in one-third 239 
of the population posing no health risk to healthy individuals even if small wounds or cuts 240 
get infected (9). However, MRSA infections of wounds can lead to more serious health 241 
implications, including necrotizing fasciitis, necrotizing pneumonia, and infective 242 
endocarditis (2). The treatment for wounds infected with MRSA is on a case-by-case basis 243 
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based on a variety of factors, including the level of intrusion into soft tissue. Treatment 244 
typically involves a combination of incision, drainage and prescription of an antibiotic. The 245 
antibiotics of choice include vancomycin, clindamycin, trimethoprim-sulfamethoxazole, 246 
tetracylcines, and oxazolidinones (17). However according to Daum et al. (7), the data 247 
comparing the effectiveness of antimicrobial agents against MRSA is lacking. Specialized 248 
treatments against MRSA include hyperbaric oxygen therapy where increased oxygen 249 
levels help promote tissue healing. 250 
 251 
Antibiotic Resistance and Virulence  252 
 Staphylococcus aureus strains are considered methicillin resistant if they contain 253 
the mec gene and have an oxacillin MIC ≥ 4 μg/mL (17). MRSA have the mobile genetic 254 
element, staphylococcal cassette chromosome, that at minimum contains the mec gene 255 
(21). Resistance occurs when a penicillin-binding protein (PBP2a) encoded on the mec 256 
gene binds with a lower affinity to beta-lactam antibiotics allowing transpeptidase 257 
activity to continue as normal for cell wall assembly (15). In addition, two regulatory 258 
components, namely mecR1-mecI and beta-lactamase genes (blaI, blaRI, and blaZ) act as 259 
negative regulators of mecA transcription leading to varied resistance levels (17). 260 
Auxiliary genes like fem affect the level of resistance by building pentaglycine cross-261 
bridges that link glycan chains enhancing the PBP2a protein (28). Salt concentration, pH, 262 
temperature, and osmolarity can affect resistance levels (28). 263 
 MRSA possesses many virulence factors that enhance its ability to colonize and 264 
proliferate in host cells.  Notably, Panton-Valentine leukocidin (PVL) is a cytotoxin that 265 
causes cell destruction and tissue death (17). In a study conducted in a Veterans Medical 266 
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Center, researchers found that 60% of all MRSA isolates contained the genes for the PVL 267 
toxin (12). Other virulence factors include alpha-hemolysin toxin, phenol soluble 268 
modulins, and arginine catabolic mobile element (17).  269 
 270 
Biofilm Formation in Wound Infections 271 
MRSA has the ability to form biofilms that increase its resistance to antibiotics, the 272 
ability to evade host immune response, and causes prolonged healing times. Biofilms form 273 
when bacteria adhere to a surface and embed themselves in a matrix of extracellular 274 
polymeric substances (EPS). The sequence of biofilm development consists of attachment 275 
to a surface, EPS production and growth of microbes, and finally maturation and 276 
dissemination (24). The development of biofilms includes quorum sensing between 277 
microorganisms and water channels that serve for delivery of nutrients and excretion of 278 
wastes (24). The ability to form biofilms is a major factor that increases the virulence of 279 
MRSA, especially in wound infections and its persistence on medical devices.  280 
The molecular mechanism of biofilm formation of MRSA is not fully understood. 281 
In one study, 48 genes were found to be induced and 84 genes repressed during biofilm 282 
formation compared to planktonic conditions indicating that biofilm formation requires an 283 
adaptive response (6). Atshan et al. (5) using qPCR demonstrated the role of genes 284 
encoding fibronectin binding protein A and B, clumping factor B, elastin binding proteins, 285 
and intracellular adhesion protein C during specific stages of biofilm formation. The study 286 
showed that biofilm formation is a complex interplay of activation of different genes in a 287 
temporal organization. In another study, Ando et al. (3) observed that MRSA isolates from 288 
patients with urinary tract infections from inserted catheters expressed higher hla, hlb, and 289 
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fnbA gene products compared to catheter-unrelated cases. Roche et al. (27) created a 290 
murine wound biofilm model to test the efficacy of antimicrobial agents on biofilms, and 291 
found that the antimicrobial agents had reduced effectiveness 24 hours after S. aureus 292 
inoculation compared to 4 hours after inoculation. 293 
 294 
Natural Antimicrobials 295 
  Emerging antibiotic resistance in pathogens is a significant and growing public 296 
health issue that directly impacts patient care. It is estimated that 63,000 patients in the 297 
United States die from hospital-acquired bacterial infections per year (1). The need for 298 
novel treatments is critical to control antibiotic resistant bacteria. A majority of the 299 
antimicrobials used in the clinical settings are derived from the golden era of antibiotic 300 
discovery from limited ecological niches and taxonomic groups. To increase diversity of 301 
compounds, research needs to be conducted for identifying potential antimicrobials from 302 
marine environments, plants, and fungi. This research focuses on the potential therapeutic 303 
application of two natural essential minerals, namely Zn and Mn in wounds infected with 304 
MRSA. Traditionally transition metals have been used for thousands of years in medicine. 305 
Egyptians used copper as an astringent, silver was used to prevent infection of surgical 306 
wounds, and mercury salts were used to treat diseases such as leprosy and tuberculosis 307 
(16). Silver is a well-known transition metal that has gained traction as an antimicrobial 308 
agent in the healthcare field for coating coat surgical tools, catheters, and furniture among 309 
other fomites. The proposed mechanism is that silver disrupts chemical bonds in bacteria 310 
cells leading to cell death (28). Commercial products like Silvazine showed zones of 311 
inhibition against all 200 tested S. aureus, staphylococci and pseudomonas aeruginosa 312 
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isolates (11). In addition, Lemire et al. (16) described the various antimicrobial 313 
mechanisms of metals, including generating reactive oxygen species, antioxidant 314 
depletion, disrupted membranes, and genotoxicity. This research will determine the 315 
antimicrobial efficacy of Zn and Mn for potential application in treating wounds infected 316 
with MRSA.  317 
 318 
Zinc and Manganese 319 
 Both Zn and Mn are naturally occurring essential microelements recommended for 320 
daily intake by the United States Food and Drug Administration. These minerals are 321 
present in a wide range of foods in addition to being used as dietary supplements. Zn is an 322 
essential mineral involved in the catalytic activity of about 100 enzymes besides playing 323 
roles in immune function, protein synthesis, DNA synthesis and cell division (21). The 324 
recommended dietary allowance for Zn for an average adult is between 8 mg for females 325 
and 11mg for males (21). Zn is known to exert antimicrobial properties against S. aureus, 326 
S. epidermis, and P. aeruginosa (4). Xie et al. (31) showed that zinc oxide had bactericidal 327 
effects on Campylobacter jejuni. McDevitt et al. (19) reported that a high Zn to Mn ratio 328 
caused increased sensitivity of Streptococcus pneumoniae to oxidative stress and 329 
polymorphonuclear leucocyte killing. Zn complexes utilized as antimicrobial wound 330 
dressings showed partial killing of S. aureus (25). Similarly, Mn is an essential trace 331 
mineral that plays a role in the development of connective tissue and hormones, and is 332 
necessary for fat and carbohydrate metabolism, blood sugar regulation, nerve function, and 333 
antioxidant production (18). The recommended daily dietary allowance of Mn is 1.8 mg in 334 
females and 2.3 mg in males. Compared to silver and Zn, Mn is not as well studied with 335 
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regards to its antimicrobial properties. Rahman et al. (26) found that the concomitant use 336 
of Mn salt with a variety of antibiotics increased the activity of the antibiotic. However, 337 
the majority of the literature on Mn is based on its use in metal complexes. To date there 338 
is no research on Mn for controlling wound infections.  339 
 340 
Summary 341 
 The objective of this study was to investigate the antimicrobial properties of Zn and 342 
Mn on MRSA for future applications in wound infection treatments. The specific 343 
objectives included determining: 344 
 345 
1. The sub inhibitory concentration (SIC) and minimum inhibitory concentration 346 
(MIC) of Zn and Mn on three strains of MRSA. 347 
2. The effect of SIC and MIC of Zn and Mn on increasing MRSA sensitivity to 348 
oxacillin. 349 
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 The emergence of Methicillin-Resistant Stapylococcus aureus has triggered an 490 
increased interest in finding alternative natural antimicrobials to control the pathogen and 491 
combat growing antibiotic resistance. This study investigated the antimicrobial effect of 492 
two naturally occurring essential minerals, zinc (Zn) and manganese (Mn) on MRSA for 493 
potential application in wound infections. The sub inhibitory concentration (SIC) and 494 
minimum inhibitory concentration (MIC) of Zn and Mn against MRSA were determined. 495 
The effect of MIC and 2x MIC of Zn and Mn in increasing MRSA susceptibility to 496 
oxacillin, and the effect of SIC and MIC of these minerals on MRSA cell adherence and 497 
invasion of human keratinocytes were investigated. The SIC and MIC of Zn and Mn 498 
against MRSA were 0.4 mM and 2.5 mM, and 1.6 mM 4.7 mM, respectively.  Both 499 
metals in combination with oxacillin were more effective in reducing MRSA than 500 
oxacillin alone. In addition, both Zn and Mn significantly reduced MRSA adhesion and 501 
invasion of human skin cells. Results indicate that the aforementioned antimicrobials can 502 
be potentially used to control MRSA wound infections, however further studies are 503 
warranted. 504 
 505 
  506 
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INTRODUCTION 507 
 Methicillin-resistant Staphylococcus aureus (MRSA) is a nosocomial and 508 
community acquired pathogen, which is one of the common causes of bacterial infection 509 
in humans (2). According to the Emerging Infections Program and National Healthcare 510 
Safety Network, it is estimated that a total of 75,000 MRSA infections occur every year 511 
(15). In addition, two in 100 people are carriers of MRSA (15). An estimated 63,000 512 
patients in the United States die each year from hospital-acquired bacterial infections (1). 513 
The symptoms of MRSA are similar to other S. aureus infections, which include 514 
impetigo, folliculitis, abscesses, pneumonia, endocarditis, and sepsis (21). MRSA 515 
infections are attributed to increased mortality rates and hospital costs contributing to a 516 
total estimate of $1.87 billion in additional costs of treating hospital-acquired infections 517 
(6). MRSA is a misnomer as strains of MRSA are resistant to a number of beta lactam 518 
antibiotics, including penicillin, amoxicillin, oxacillin, methicillin, cephalosporin, and 519 
carbapenem (3). 520 
The majority of MRSA infections start in wounds and other breaches to the 521 
integrity of the skin usually caused by trauma, surgery, or medical devices. Approaches 522 
to treatment of skin and soft tissue infections include a combination of incision, drainage 523 
and antimicrobial therapy (12). Vancomycin is the antibiotic of choice against MRSA 524 
although there are growing concerns of vancomycin resistance (22). Changes in MRSA 525 
vancomycin susceptibility have been associated with increasing minimum inhibitory 526 
concentrations, increasing frequency of hetero-resistant vancomycin-intermediate S. 527 
aureus and adverse clinical outcomes (21). Alternatives to vancomycin include, 528 
clindamycin, tetracylines, tigecycline, linezolid, and daptomycin (4). Simor et al. (22) 529 
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found there was no significant difference in clinical outcomes of MRSA infections when 530 
comparing vancomycin to other antimicrobial agents, namely teicoplanin, trimethoprim-531 
sulphamethoxazole, and linezolid. It raises significant concern that MRSA is becoming 532 
increasingly drug resistant even to newer antimicrobial agents such as linezolid, 533 
vancomycin, teicoplanin, and daptomycin (10). S. aureus has the unique ability to 534 
respond to new antibiotics with the development of resistance mechanisms such as 535 
decreased affinity for beta-lactam antibiotics via penicillin-binding protein 2a, decreased 536 
affinity for vancomycin via a D-Ala-D-lac substitution in peptidoglycan formation, and 537 
efflux pumps that work against fluoroquinolones and tetracylines (18).  538 
Metals have been used since antiquity as antimicrobials in medicine and 539 
agriculture (11). The use of metals in healthcare settings is well known through metal-540 
impregnated dressings and antimicrobial metal nanoparticles (11). Metals such as silver 541 
have gained attraction as a viable antimicrobial in the healthcare field with their use to 542 
coat surgical tools, catheters, and furniture. Topical silver has broad-spectrum 543 
antimicrobial activity that is used in wound dressings. Commercial products like 544 
Silvazine showed inhibition against 200 tested S. aureus, staphylococci and P. 545 
aeruginosa isolates (7).  546 
        Zn is an essential mineral involved in the catalytic activity of about 100 enzymes 547 
in addition to playing roles in immune function, protein synthesis, DNA synthesis and cell 548 
division (17). Mn is an essential trace mineral that plays a role in the development of 549 
connective tissue and hormones, and is necessary for fat and carbohydrate metabolism, 550 
blood sugar regulation, nerve function, and antioxidants (5). The objective of this study 551 
was to evaluate the efficacy of Zn and Mn as potential antimicrobials against wounds 552 
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infected with MRSA. The specific objectives included establishing the SIC and MIC of Zn 553 
and Mn against MRSA, determining the effect of Zn and Mn on increasing MRSA 554 
sensitivity to oxacillin, and determining the effect of Zn and Mn on MRSA cell adhesion 555 
and invasion onto human keratinocytes. 556 
 557 
MATERIALS AND METHODS 558 
 559 
 560 
Bacterial Strains 561 
  562 
Three clinical strains of MRSA were used in this study (US 384, US 192, and US 563 
194). All bacteriological media used in the study was purchased form Difco (Sparks, MD, 564 
USA). For the preparation of inoculum, each strain was grown separately in 10 mL of 565 
sterile tryptic soy broth (TSB) at 37°C for 24 hours. The cells were separated by 566 
centrifugation (3,600 x g for 10 min at 4°C) and resuspended in phosphate buffered saline 567 
(PBS, pH 7.2). Subsequently 0.1 mL from each strain was added to a tube of 9.9 mL of 568 
PBS. The bacterial population in each culture was determined by serial dilution and 569 
plating of 0.1 mL aliquots on tryptic soy agar (TSA) plates and incubating the plates at 570 
37°C for 24 hours.  571 
 572 
Determination of Sub Inhibitory Concentration (SIC) and Minimum Inhibitory 573 
Concentration (MIC) 574 
 575 
 Mn and Zn were purchased from Sigma-Aldrich Chemical Co. (St. Louis, MO, 576 
USA). Mn was in the form MnCl2 and Zn was in the form ZnSO4. The SIC and MIC of 577 
Mn and Zn against each MRSA strain were determined as previously published (8). 578 
Twenty-four well plates containing sterile TSB was separately inoculated with each strain 579 
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of MRSA (~ 4.5 log CFU/mL) with varying concentrations of each mineral. The plates 580 
were then incubated at 37°C for 24 hours. After incubation each well was mixed 581 
thoroughly, serially diluted, plated on TSA, and incubated at 37°C for 24 hours. 582 
Duplicate samples were included for each treatment at each concentration for each strain, 583 
and the whole study was replicated three times. The SIC was taken as the highest 584 
concentration of Zn or Mn that did not inhibit MRSA after 24 hours of incubation. The 585 
MIC of Zn or Mn that inhibited visible growth of the bacteria after 24 hours incubation 586 
was taken as the MIC. 587 
 588 
 589 
Effect of Mn and Zn on Increasing MRSA Sensitivity to Oxacillin 590 
  591 
 Methicillin is no longer commercially available in the United States and oxacillin 592 
is more stable during storage (3). Therefore oxacillin was used as the antibiotic in this 593 
study. Twenty-four well plates containing sterile TSB were inoculated with each strain of 594 
MRSA (~4.5 log CFU/mL) followed by the addition of the break point concentration of 595 
oxacillin against MRSA(4  µg/mL) in combination with MIC and SIC of each metal. The 596 
plates were incubated at 37°C for 24 hours. After incubation each well was thoroughly 597 
mixed, serially diluted, plated, and incubated at 37°C for 24 hours.  598 
 599 
Keratinocyte Cell Culture 600 
 601 
 MRSA cell adhesion and invasion were determined by a previous protocol (9). 602 
Human skin keratinocyte, HEK001 (ATCC CRL-2404) was obtained from the American 603 
Culture Collection (Manassas, Virginia). HEK001 cells were grown in a 25 cm2 cell 604 
culture flask containing keratinocyte serum free (KSFM) supplemented with human 605 
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recombinant epidermal growth factor (Invitrogen, Carlsbad, CA, USA) at 37°C for 24-48 606 
hours in an aerobic incubator containing 5% CO2. 607 
 608 
Adhesion and Invasion Assay 609 
  610 
 The effect of MIC of Zn and Mn on MRSA adhesion and invasion of HEK001 611 
keratinocyte cells was determined as previously described (16). Twenty four-well tissue 612 
culture plates (BD, Franklin Lakes, NJ) was seeded with 105 cells/well, and incubated at 613 
37°C for 24 hours in a 5% CO2 incubator to form a monolayer. MRSA was grown to mid 614 
log phase at 37°C, washed and re-suspended in KSFM with MIC of Zn and Mn. Bacteria 615 
suspended in KSFM was used as control. Aliquots of 100 μL of the bacterial suspension 616 
containing ~ 6 log CFU/ well (MOI 1:10) were inoculated in duplicates into the HEK001 617 
monolayer, and incubated at 37°C in 5% CO2 incubator for 2 hours. For adhesion assay, 618 
the infected monolayer after incubation was washed three times with PBS, and the cells 619 
were lysed using 0.1% Triton X-100 (Invitrogen, City, state). The number of viable 620 
adhered bacteria was enumerated by serial dilution and culturing on TSA plates. For the 621 
invasion assay, the HEK001 monolayer was washed three times with PBS, followed by 622 
incubation for 2 hours in KSFM containing gentamicin (100 microgram/ml) (Invitrogen) 623 
in order to kill the extracellular bacteria. Subsequently, the wells were washed three times 624 
with PBS and the cells were lysed using 0.1% Triton X-100 to release the intracellular 625 
bacteria. The number of invaded bacteria was enumerated by serial dilution in PBS and 626 
culturing on TSA plates. Both adhesion and invasion assays were done in duplicates and 627 





Statistical Analysis 632 
 633 
 All experiments were a completely randomized design. The data from 634 
independent replicate trials of each experiment were averaged and analyzed using Proc 635 
GENMOD, SAS 9.4 version (SAS Institute, Cary, NC) Variations among replicates were 636 
used as the error term. Data was expressed as least squares means and differences were 637 
considered significant at P <0.05.  638 
 639 
 640 
RESULTS AND DISCUSSION 641 
 642 
    The emergence of antibiotic resistance in pathogenic microorganisms, including 643 
MRSA has triggered investigations to identify novel antimicrobials. In study, two 644 
essential minerals, namely Zn and Mn were investigated for their potential to control 645 
MRSA, especially for wound infections.  646 
 The SIC and MIC of Zn and Mn against MRSA were 0.4 mM and 2.5 mM, and 647 
1.6 mM 4.7 mM, respectively.   The effect of MIC and 2x MIC of Zn and Mn on 648 
increasing MRSA sensitivity to oxacillin is depicted in Fig. 1 and 2. The 2x MIC was 649 
used in lieu of comparing SIC and MIC of the metals because preliminary studies showed 650 
SIC of both metals did not increase the sensitivity of MRSA to oxacillin. In control tubes, 651 
all three strains grew to an average of 8.5 log CFU/mL. In the presence of breakpoint 652 
concentration of oxacillin, as expected the MRSA strains being resistant to the antibiotic 653 
grew by ~ 2 to 3 log CFU/mL. In addition, in the presence of the MIC of Zn and Mn, 654 
bacterial count after 24 h did not change significantly from the inoculation of level of 4.5 655 
log CFU/mL. However, when MRSA was grown in the presence of antibiotic and the 656 
MIC or 2x MIC of Zn or Mn, its growth after 24 h was significantly decreased in 657 
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comparison to that in tubes containing oxacillin alone  (P < 0.05). For example, the 658 
MRSA counts recovered from tubes containing oxacillin and Zn or Mn were ~ 3 to 4 log 659 
CFU/mL as against ~ 6 to 7log CFU/mL in samples containing only oxacillin. The trend 660 
was observed in all three MRSA strains.  Except in strain USA 384, there was no 661 
difference in bacterial reductions between samples containing the MIC and 2x MIC Zn or 662 
Mn with oxacillin  663 
 The effect of SIC and MIC of Zn and Mn on MRSA adhesion to human 664 
keratinocytes is depicted in Fig. 3 and 4. Compared to control samples where ~ 6 to 7 log 665 
CFU/mL of MRSA attached to the keratinocytes, the SIC of Zn brought about ~ 2.5 log 666 
CFU/mL reduction in bacterial count across all three strains (P<0.05). Similarly, the MIC 667 
of Zn reduced the attachment of MRSA onto skin cells by 3.0 log CFU/ml in all three 668 
strains (P<0.05). Similar results were observed in the experiments with Mn, where the 669 
SIC of Mn reduced the attached MRSA by about 2.4 log CFU/mL in all three strains. The 670 
MIC of Mn on the other hand brought about a 3.0 log CFU/mL reduction in attached 671 
bacterial. 672 
 The effect of SIC and MIC of Zn and Mn on MRSA invasion of human 673 
keratinocytes is depicted in Fig. 5 and 6.  In control wells with no Zn and Mn, ~ 4 to 4.5 674 
log CFU/mL of MRSA attached the cells. However, the SIC and MIC of Zn decreased 675 
the invaded bacteria by ~1.7 log CFU/mL 2.1 log CFU/mL, respectively. A similar 676 
magnitude of reduction in the invaded MRSA counts was observed in Mn-treated cells. 677 
 The aforementioned results indicate that Zn and Mn were effective in increasing 678 
the sensitivity of MRSA to oxacillin when the antibiotic was combined with the minerals. 679 
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In addition, it was found both minerals were effective in reducing MRSA attachment and 680 
invasion of human keratinocytes.  681 
Although the exact mechanism behind the anti-MRSA effect of Zn and Mn is not clear, 682 
the proposed antimicrobial mechanisms of action of metals include creation of reactive 683 
oxygen species, antioxidant depletion, oxidation of side chains leading to protein 684 
dysfunction, interference with nutrient assimilation, and genotoxicity in microbes (11). 685 
 The recommended daily dietary allowance of Zn is 8 mg for females and 11 mg 686 
for males with a tolerable upper intake level of 40 mg (17). The recommended daily 687 
dietary allowance of Mn is 1.8 for females and 2.3 mg for males with a tolerable upper 688 
intake level of 11 mg (14). Although the concentrations of minerals used in this 689 
experiment are at or above oral intake levels, the route of intended application is topical 690 
on wound infections rather than oral. To conclude, the results of this study indicate that 691 
Zn and Mn have the potential to be used as effective and safe antimicrobials to combat 692 
wound infections of MRSA. However, follow up studies in an in vivo a wound model are 693 
necessary in addition to experiments for delineating the antimicrobial mechanisms of Zn 694 




 Results of this study indicate that Zn and Mn increased the sensitivity of MRSA 699 
to oxacillin. In addition, Zn and Mn reduce the amount of bacteria that both adhere and 700 
invade onto human keratinocytes. Therefore, these metals show potential as 701 
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MRSA Sensitivity to Oxacillin Study 785 
 786 
 787 
Figure 1 Effect of MIC and 2x MIC of Zn on increasing MRSA sensitivity to oxacillin in 3 strains. Bars with 788 
different letters are significantly different from each other (P<0.05) 789 
 790 
 791 
Figure 2 Effect of MIC and 2x MIC of Mn on increasing MRSA sensitivity to oxacillin in 3 strains. Bars with 792 

































































































































































































































































MRSA Cell Adhesion onto Human Keratinocytes 794 
 795 
 796 
Figure 3: Effect of SIC and MIC of Zn on MRSA adhesion to human keratinocytes. Bars with different letters 797 
are significantly different from each other (P<0.05) 798 
 799 
Figure 4: Effect of SIC and MIC of Mn on MRSA adhesion to human keratinocytes. Bars with different letters 800 





























































































































































MRSA Cell Invasion onto Human Keratinocytes 802 
 803 
 804 
Figure 5: Effect of SIC and MIC of Zn on MRSA invasion of human keratinocytes. Bars with different letters 805 
are significantly different from each other (P<0.05) 806 
 807 
Figure 6 Effect of SIC and MIC of Mn on MRSA invasion of human keratinocytes. Bars with different letters 808 
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